表紙
市場調査レポート

世界の遺伝子治療市場の分析

Global Gene Therapy Market Forecast to 2020

発行 RNCOS E-Services Pvt. Ltd. 商品コード 235806
出版日 ページ情報 英文 182 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
世界の遺伝子治療市場の分析 Global Gene Therapy Market Forecast to 2020
出版日: 2016年01月01日 ページ情報: 英文 182 Pages
概要

当レポートでは、世界の遺伝子治療市場について調査分析し、業界の動向と促進要因、応用別分析、地域別分析、開発段階別パイプライン分析などを提供し、主要企業のプロファイルも含めてお届けいたします。

第1章 アナリストの見解

第2章 分析手法

第3章 遺伝子治療:イントロダクション

第4章 産業概要

  • 市場促進要因
    • 従来の癌治療法の失敗
    • 先進国で遺伝子治療の商品化に焦点を絞る
    • 慢性的および致命的な疾患の罹患率の増加
    • ベンチャー投資企業の関心の高まり
  • 市場抑制要因
    • 厳しい規制法と安全性に対する懸念
    • 最新技術の潜在的な危険性
    • 高価な遺伝治療薬
  • 市場機会
    • 欧州での遺伝治療薬の認可
    • B型血友病に対する遺伝子治療が重要な機会を提供
  • 産業動向
    • 遺伝子サイレンシング(遺伝子抑制):躍進を遂げる
    • 最先端治療:遺伝子治療と幹細胞技術を組み合わせる
    • 免疫不全症候群:遺伝子治療の焦点
    • ナノテクノロジー:遺伝子治療を活性化
    • 遺伝子治療:失明の治療に新しい希望
    • 遺伝子治療:癌の潜在的治療法として
  • 勝利の法則
    • R&D活動への投資

第5章 遺伝子治療の臨床試験評価およびパイプライン分析

  • 臨床試験
    • 地域別
    • 症状別
    • 遺伝子タイプ別
    • ベクター別
    • 臨床試験の相別
  • パイプライン分析

第6章 規制状況および償還シナリオ

  • 主な地域別市場
    • 米国
    • カナダ
    • 欧州
    • 日本
    • 中国
    • インド
    • オーストラリア
  • 世界市場における償還シナリオ

第7章 上市済の遺伝子治療薬

  • Neovasculgen
  • Glybera
  • Gendicine, Rexin-G, Oncorine
    • Gendicine
    • Rexin G
    • Oncorine

第8章 世界の遺伝子治療市場

第9章 応用領域別市場

  • 心血管疾患
  • 感染症
  • 神経疾患
  • 遺伝子疾患
  • その他

第10章 地域別市場規模

  • 北米
  • 欧州
  • アジア
  • その他地域

第11章 競合環境

  • 各企業が採っている戦略
    • 戦略的協力
    • 買収
    • 資金調達および投資
  • 遺伝子治療において成長を遂げた企業(2015年)

第12章 主要企業分析

  • Spark Therapeutics, LLC
  • ViroMed Co. Ltd. dba VM BioPharma
  • Advantagene Inc.
  • Bluebird Bio
  • Sanofi
  • Vical Inc.
  • Oxford BioMedica Plc
  • Genethon
  • uniQure N.V.
  • Human Stem Cells Institute
  • Shanghai Sunway Biotech Co. Ltd.
  • Sibiono GeneTech Co. Ltd.

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Gene therapy is one of the most widely researched fields in the healthcare industry. The high potential of gene therapy to cure various chronic diseases makes it a popular research area. Various researches are being performed across the globe to explore the potential of gene therapy for the treatment of incurable diseases, such as diabetes, cancer, and HIV amongst others.

According to RNCOS' new research report "Global Gene Therapy Market Forecast to 2020", most of the gene therapy researches are being focused on finding the treatment for cancer, followed by genetic diseases and neurological disorders, respectively. In this context, the gene therapy application chapter of the report provides a comprehensive overview of various diseases in which the gene therapy is used, along with the current and future market size of gene therapy for particular disease and its geographical break up. Primarily, the gene therapy market is dominated by oncology applications, with several companies and academic institutions focusing on novel and 'difficult to treat' cancers. Other therapeutic areas seeking developments in gene therapy include monogenic diseases, cardiovascular diseases, infectious diseases, inherited blindness and neurological diseases. Furthermore, the chapter also provides details regarding the various aspects of the clinical trials in the different gene therapy application by phases, vector types, etc.

The major part of the revenue of gene therapy market is generated from research phase. Most of the gene therapy products are in research phases, only few products have been commercialized till date. The report also provides the sales of major marketed gene therapy products, and the list of the products in clinical/pre-clinical research along with their clinical phases.

The companies operating in the gene therapy market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms which are aiding them to develop new products. The study highlights the applications for which the investments have been received.

North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Based on the geography, the market is divided into four regions, namely, North America, Europe, Asia, and Rest of the World. The report provides the market for each of the geography, along with its forecast till 2020.

RNCOS, in its report, further covers how major trends and drivers, mainly gene silencing, advanced therapies combining gene therapy and stem cell technology, immunodeficiency syndromes, growing interest of venture capital firms, etc. will propel the industry's growth. An analysis has also been done of a few factors limiting the growth of the industry. The report also provides insights regarding the strategies adopted by the players from 2013 to 2015 for enhancing their market share. Finally, with a view to understand the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global gene therapy market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Gene Therapy - An Introduction

  • 3.1 Classification of Gene Therapy Techniques
  • 3.2 Physical Methods of Gene Transfer
    • 3.2.1 Electroporation
    • 3.2.2 Hydrodynamic
    • 3.2.3 Microinjection
    • 3.2.4 Particle Bombardment
    • 3.2.5 Ultrasound-Mediated Transfection
  • 3.3 Vectors for Gene Therapy
    • 3.3.1 Viral Vectors
    • 3.3.2 Non Viral Vectors

4. Industry Overview

  • 4.1 Market Drivers
    • 4.1.1 Failure of Conventional Therapies to Treat Cancers
    • 4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations
    • 4.1.3 Rising Incidence of Chronic and Life Threatening Diseases
    • 4.1.4 Growing Interest of Venture Capital Firms
  • 4.2 Market Restraints
    • 4.2.1 Stringent Regulatory Laws & Safety Concerns
    • 4.2.2 Pitfalls in Current Technique
    • 4.2.3 High Cost of the Gene Therapy Drugs
  • 4.3 Market Opportunities
    • 4.3.1 Approval of Gene Therapy Drug in Europe
    • 4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity
  • 4.4 Industry Trends
    • 4.4.1 Gene Silencing: Gaining Momentum
    • 4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
    • 4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
    • 4.4.4 Nanotechnology: Empowering Gene Therapy
    • 4.4.5 Gene Therapy: A New Hope to Treat Blindness
    • 4.4.6 Gene Therapy: Potential Cure for Cancer
  • 4.5 Winning Imperatives
    • 4.5.1 Investment in R&D Activities

5. Clinical Trial Assessment & Pipeline Analysis

  • 5.1 Clinical Trials
    • 5.1.1 By Geography
    • 5.1.2 By Indication
    • 5.1.3 By Gene Type
    • 5.1.4 By Vector
    • 5.1.5 By Clinical Trial Phase
  • 5.2 Pipeline Analysis

6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario

  • 6.1 Regulatory Landscape
    • 6.1.1 US
    • 6.1.2 Canada
    • 6.1.3 Europe
    • 6.1.4 Japan
    • 6.1.5 China
    • 6.1.6 India
    • 6.1.7 Australia
  • 6.2 Reimbursement Scenario in Global Market

7. Marketed Gene Therapies

  • 7.1 Neovasculgen
  • 7.2 Glybera
  • 7.3 Gendicine, Rexin-G, Oncorine
    • 7.3.1 Gendicine
    • 7.3.2 Rexin G
    • 7.3.3 Oncorine

8. Global Gene Therapy Market

9. Gene Therapy Market by Application

  • 9.1 Oncology
    • 9.1.1 Clinical Trials
    • 9.1.1 Prevalence
    • 9.1.3 Market Outlook
  • 9.2 Cardiovascular Diseases
    • 9.2.1 Clinical Trials
    • 9.2.2 Prevalence
    • 9.2.3 Market Outlook
  • 9.3 Infectious Diseases
    • 9.3.1 Clinical Trials
    • 9.3.2 Prevalence
    • 9.3.3 Market Outlook
  • 9.4 Neurological Diseases
    • 9.4.1 Clinical Trials
    • 9.4.2 Prevalence
    • 9.4.3 Market Outlook
  • 9.5 Genetic Diseases
    • 9.5.1 Clinical Trials
    • 9.5.2 Prevalence
    • 9.5.3 Market Outlook
  • 9.6 Others
    • 9.6.1 Clinical Trials
    • 9.6.2 Prevalence
    • 9.6.3 Market Outlook

10. Global Gene Therapy Market Size by Geography

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia
  • 10.4 Rest of the World (RoW)

11. Competitive Landscape

  • 11.1 Strategies Adopted by Various Players
    • 11.1.1 Strategic Collaborations
    • 11.1.2 Acquisitions
    • 11.1.3 Funding & Investments
  • 11.2 Companies Progress in Gene Therapy In 2015

12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses)

  • 12.1 Spark Therapeutics, LLC
  • 12.2 ViroMed Co. Ltd. dba VM BioPharma
  • 12.3 Advantagene Inc.
  • 12.4 Bluebird Bio
  • 12.5 Sanofi
  • 12.6 Vical Inc.
  • 12.7 Oxford BioMedica Plc
  • 12.8 Genethon
  • 12.9 uniQure N.V.
  • 12.10 Human Stem Cells Institute
  • 12.11 Shanghai Sunway Biotech Co. Ltd.
  • 12.12 Sibiono GeneTech Co. Ltd.

List of Figures:

  • Figure 4-1: Global - Major Venture Capitalist Investments in Gene Therapy Product Development (Billion US$), 1999 to 2015
  • Figure 5-1: Global - Number of Approved Gene Therapy Clinical Trials (2005-July 2015)
  • Figure 5-2: Global - Geographical Distribution of Gene Therapy Clinical Trials by Continents (%)
  • Figure 5-3: Global - Geographical Distribution of Gene Therapy Clinical Trials by Countries (%)
  • Figure 5-4: Global - Gene Therapy Clinical Trials by Indication (%)
  • Figure 5-5: Global - Gene Therapy Clinical Trials by Types of Gene Transferred (%)
  • Figure 5-6: Global - Gene Therapy Clinical Trials by Vectors (%)
  • Figure 5-7: Global - Gene Therapy Clinical Trials by Phase (%)
  • Figure 6-1: US - Number of New Cell Therapy and Gene Therapy Products Submission to FDA (2003-2010)
  • Figure 6-2: Japan - Evaluation System of Gene Therapy Clinical Trial
  • Figure 7-1: Global - Neovasculgen Sales (Million US$), 2013 & 2014
  • Figure 8-1: Global - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-1: Global - Gene Therapy Market by Application (%), 2015
  • Figure 9-2: Global - Gene Therapy Market by Application (%), 2020
  • Figure 9-3: Global - Oncology Gene Therapy Clinical Trials by Vectors (%)
  • Figure 9-4: Global - Oncology Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-5: Global - Oncology Gene Therapy Clinical Trials by Type (%)
  • Figure 9-6: Global - Oncology Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-7: Global - Oncology Gene Therapy Market by Geography (%), 2015
  • Figure 9-8: Global - Key Cardiovascular Diseases Gene Therapy Ongoing Clinical Trials
  • Figure 9-9: Global - Cardiovascular Disease Gene Therapy Clinical Trials by Vectors (%)
  • Figure 9-10: Global - Cardiovascular Disease Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-11: Global - Cardiovascular Disease Gene Therapy Clinical Trials by Type (%)
  • Figure 9-12: Global - Cardiovascular Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-13: Global - Cardiovascular Disease Gene Therapy Market by Geography (%), 2015
  • Figure 9-14: Global - Infectious Disease Gene Therapy Clinical Trials by Vectors (%)
  • Figure 9-15: Global - Infectious Disease Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-16: Global - Infectious Disease Gene Therapy Clinical Trials by Type (%)
  • Figure 9-17: Global - Infectious Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-18: Global - Infectious Disease Gene Therapy Market by Geography (%), 2015
  • Figure 9-19: Global - Neurological Diseases Gene Therapy Clinical Trials by Vector (%)
  • Figure 9-20: Global - Neurological Diseases Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-21: Global - Neurological Diseases Gene Therapy Clinical Trials by Type (%)
  • Figure 9-22: Global - Neurological Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-23: Global - Neurological Disease Gene Therapy Market by Geography (%), 2015
  • Figure 9-24: Global - Genetic Disease Gene Therapy Clinical Trials by Vector (%)
  • Figure 9-25: Global - Genetic Disease Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-26: Global - Genetic Disease Gene Therapy Clinical Trials by Type (%)
  • Figure 9-27: Global - Genetic Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-28: Global - Genetic Disease Gene Therapy Market, by Geography (%), 2015
  • Figure 9-29: Global - Other Disease Gene Therapy Clinical Trials by Type (%)
  • Figure 9-30: Global - Other Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-31: Global - Other Disease Gene Therapy Market by Geography (%), 2015
  • Figure 10-1: Global - Gene Therapy Market by Geography (%), 2015
  • Figure 10-2: North America - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-3: Europe - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-4: Asia - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-5: Asia - Number of Gene Therapy Laboratories by Major Asian Countries (2014)
  • Figure 10-6: India - Number of Gene Therapy Laboratories (2000, 2010 & 2013)
  • Figure 10-7: Rest of the World - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 11-1: Key Growth Strategies Adopted by Key Players (2013 to 2015)
  • Figure 11-2: Key Players Focusing on Strategic Collaborations (2013 to 2015)
  • Figure 11-3: Key Players Focusing on Strategic Acquisitions (2013 to 2015)
  • Figure 11-4: Key Players Focusing on Funding & Investments (2013 to 2015)
  • Figure 11-5: Companies Progress in Gene Therapy till 2015

List of Tables:

  • Table 4-1: US - Gene Therapies under Development
  • Table 4-2: Europe - Gene Therapies under Development
  • Table 4-3: Gene Therapy Companies Funded by Venture Capital Firms
  • Table 4-4: Current Status of Clinical Trials for Hemophilia
  • Table 5-1: Human Gene Transfer Trials Approved by Condition
  • Table 5-2: Global - Key Gene Therapy Ongoing Clinical Trials
  • Table 6-1: China - Key Players and their Products in Gene Therapy
  • Table 9-1: Global - Key Oncology Gene Therapy Ongoing Clinical Trials
  • Table 9-2: Global - Oncology Incidence by Geography ('000), 2015 & 2020
  • Table 9-3: Global - Key Infectious Disease Gene Therapy Ongoing Clinical Trials
  • Table 9-4: Global - HIV Prevalence & Incidence by Geography ('000), 2014
  • Table 9-5: Global - Key Neurological Disease Gene Therapy Ongoing Clinical Trials
  • Table 9-6: Global - Parkinson Disease Prevalence by Geography (Million), 2010
  • Table 9-7: Global - Key Genetic Disease Gene Therapy Ongoing Clinical Trials
  • Table 9-8: Global - Hemophilia Prevalence by Geography, 2010 & 2013
  • Table 9-9: Global - Key Other Disease Gene Therapy Ongoing Clinical Trials
  • Table 12-1: Spark Therapeutics LLC - Clinical Pipeline in Gene Therapy
  • Table 12-2: ViroMed Co. Ltd. - Clinical Pipeline in Gene Therapy
  • Table 12-3: Advantagene Inc. - Clinical Pipeline in Gene Therapy
  • Table 12-4: Bluebird Bio - Clinical Pipeline in Gene Therapy
  • Table 12-5: Sanofi - Clinical Pipeline in Gene Therapy
  • Table 12-6: Vical Inc. - Clinical Pipeline in Gene Therapy
  • Table 12-7: Oxford Biomedica Plc - Clinical Pipeline in Gene Therapy
  • Table 12-8: Genethon - Clinical Pipeline in Gene Therapy
  • Table 12-9: UniQure N.V. - Clinical Pipeline in Gene Therapy
  • Table 12-10: Human Stem Cells Institute - Clinical Pipeline in Gene Therapy
  • Table 12-11: Shanghai Sunway Biotech Co. Ltd. - Clinical Pipeline in Gene Therapy
  • Table 12-12: Sibiono GeneTech Co. Ltd. - Clinical Pipeline in Gene Therapy
Back to Top